$-0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)

September 17, 2017 - By Linda Rogers

 $ 0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)
Investors sentiment increased to 1.29 in Q4 2016. Its up 0.05, from 1.24 in 2016Q3. It increased, as 9 investors sold Enzo Biochem, Inc. shares while 29 reduced holdings. 13 funds opened positions while 36 raised stakes. 23.43 million shares or 0.05% more from 23.42 million shares in 2016Q3 were reported.
Mckinley Ltd Delaware stated it has 0.09% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). 81,446 were accumulated by Corsair Mgmt L P. Bancorp Of New York Mellon reported 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Susquehanna Ltd Liability Partnership holds 59,969 shares. Millennium Management Lc, New York-based fund reported 101,622 shares. Pennsylvania-based Sei Investments has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Deutsche Fincl Bank Ag invested in 0% or 27,818 shares. Bridgeway Mngmt, Texas-based fund reported 322,700 shares. City reported 120 shares. Walleye Trading Ltd Limited Liability Company holds 0% or 38,100 shares in its portfolio. Blackrock Fund Advsr accumulated 1.28 million shares. Citigroup invested in 0% or 40,895 shares. Nine Chapters Capital Limited Liability Company owns 30,900 shares. Vanguard Gru holds 0% or 1.53 million shares in its portfolio. Tfs Ltd Liability Corporation invested in 0.03% or 17,209 shares.

Since June 13, 2017, it had 0 buys, and 1 sale for $160,054 activity.

Wall Street await Enzo Biochem, Inc. (NYSE:ENZ) to release earnings on October, 12. Analysts forecast earnings per share of $-0.02, up exactly $0.02 or 50.00 % from 2014’s $-0.04 EPS. The stock decreased 0.73% or $0.08 on September 15, reaching $10.86. About 391,420 shares traded or 142.73% up from the average. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since September 17, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce services and products. The company has market cap of $502.73 million. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. It has a 15.26 P/E ratio. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem’s (ENZ) Management on Q4 2016 Results – Earnings Call Transcript” on October 14, 2016, also Seekingalpha.com with their article: “Enzo Biochem (ENZ) on Q3 2017 Results – Earnings Call Transcript” published on June 09, 2017, Businesswire.com published: “Enzo Biochem Reports Delaware Court Ruling” on June 29, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem Rounds The Corner” published on July 10, 2017 as well as Zacks.com‘s news article titled: “Looking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great …” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.